Clinical trial
A Phase 2a, Open-Label Biomarker Study of IC14 for the Treatment of Patients With
NCT03474263 is registered in ClinicalTrials.gov with Implicit Bioscience as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, Open-Label Biomarker Study of IC14 for the Treatment of Patients With
- Lead sponsor
- Implicit Bioscience
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- September 1, 2019
- Completion date
- July 12, 2021
- Enrollment
- 0 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.